JP Morgan initiated coverage on Enfusion with a new price target
$ENFN
Computer Software: Prepackaged Software
Technology
JP Morgan initiated coverage of Enfusion with a rating of Neutral and set a new price target of $12.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/10/2024 | $11.00 | Overweight | Morgan Stanley |
| 2/28/2024 | $9.00 → $8.00 | Neutral → Sell | Goldman |
| 1/30/2024 | $11.00 → $9.00 | Neutral → Underweight | JP Morgan |
| 11/7/2023 | $9.00 | Neutral | UBS |
| 4/3/2023 | $11.00 | Neutral | Piper Sandler |
| 3/15/2023 | $12.00 | Neutral | JP Morgan |
| 1/4/2023 | $15.00 → $10.00 | Neutral → Underperform | BofA Securities |
| 1/3/2023 | $13.00 → $12.00 | Equal-Weight → Overweight | Morgan Stanley |
SCHEDULE 13D/A - Enfusion, Inc. (0001868912) (Subject)
425 - Enfusion, Inc. (0001868912) (Subject)
425 - Enfusion, Inc. (0001868912) (Subject)
Morgan Stanley resumed coverage of Enfusion with a rating of Overweight and set a new price target of $11.00
Goldman downgraded Enfusion from Neutral to Sell and set a new price target of $8.00 from $9.00 previously
JP Morgan downgraded Enfusion from Neutral to Underweight and set a new price target of $9.00 from $11.00 previously
SC 13G/A - Enfusion, Inc. (0001868912) (Subject)
SC 13G/A - Enfusion, Inc. (0001868912) (Subject)
SC 13G/A - Enfusion, Inc. (0001868912) (Subject)
FTV Capital, a leading sector-focused growth equity investment firm, today announced its inclusion for the fourth consecutive year on Inc.'s annual Founder-Friendly Investors list, which honors the private equity, venture capital firms and lenders with a track record of backing founder-led companies. This year's list recognizes 269 firms that believe in backing founder-led businesses and helping them thrive, demonstrated by their successful track records of collaboration and remaining actively involved with their portfolio companies to drive growth. "We are honored to be recognized again by Inc. for our ongoing commitment to serving as a collaborative, strategic partner to founders and ent
Appointments of Arman Artuc to Head of Engineering, and Jesper Cordes to Head of Client Services Americas, Will Further Elevate Enfusion's Operations as an Investment Technology Industry Leader Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, announced today the appointments of Arman Artuc to Head of Engineering and Jesper Cordes to Head of Client Services Americas. These additions to the leadership team reinforce the company's position as a global leader in investment technology and services, which enables Enfusion to continue to attract top-performing industry experts and innovators to its ranks. Enfusion is s
Transformative acquisition will position ZEMA as global leader in offering high-quality enterprise data management and analytics for the energy and commodities industry ZEMA Global Data Corporation (formerly ZE PowerGroup), a leading provider of enterprise data management and analytics for the commodity and energy sectors, today announced its plans to acquire Morningstar Commodity Data, a provider of commodities and energy data and insights. The transaction is expected to close later this month. The business will serve a diverse portfolio of over 200 enterprises with an expanded product offering and broader geographic operations to support customers around the world. The announcement come
Investor Conference Call Scheduled for Today at 8:30 a.m. ET Clearwater Analytics (NYSE:CWAN) ("Clearwater") and Enfusion, Inc. (NYSE:ENFN) ("Enfusion") today announced their entry into a definitive merger agreement for Clearwater to acquire Enfusion, a leader in software-as-a-service (SaaS) solutions for the investment management and hedge fund industry. The purchase price is $11.25 per share, delivered in an approximately equal mix of cash and stock. Additionally, Clearwater will pay $30 million to terminate Enfusion's tax receivable agreement (TRA). This equates to a purchase price of approximately $1.5 billion. This press release features multimedia. View the full release here: https
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, has posted its third quarter 2024 financial results as part of its Q3 2024 Shareholder Letter which can be viewed by navigating to the Financials section of its Investor Relations website at http://ir.enfusion.com. 3Q24 Earnings Conference Call Management will host a conference call today, November 4, 2024, at 8:30 AM ET to discuss the results. To pre-register for the live teleconference of the second quarter earnings call, please use this link. To access this call, dial (888) 596-4144. The conference ID number is 9652536. The earnings conference call will also
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced it will release its third quarter 2024 financial results before the U.S. financial markets open on Monday, November 4, 2024. Management will host a conference call and webcast that same morning at 8:30 AM (ET) / 5:30 AM (PT) to discuss the results. To access this call, dial (888) 596-4144. The conference ID number is 9652536. A live webcast of this conference call will be available on the Investor Relations page of Enfusion's website, http://ir.enfusion.com, and a replay will be archived on the website as well. About Enfusion Enfusion's investment
Investor Conference Call Scheduled for Today at 8:30 a.m. ET Clearwater Analytics (NYSE:CWAN) ("Clearwater") and Enfusion, Inc. (NYSE:ENFN) ("Enfusion") today announced their entry into a definitive merger agreement for Clearwater to acquire Enfusion, a leader in software-as-a-service (SaaS) solutions for the investment management and hedge fund industry. The purchase price is $11.25 per share, delivered in an approximately equal mix of cash and stock. Additionally, Clearwater will pay $30 million to terminate Enfusion's tax receivable agreement (TRA). This equates to a purchase price of approximately $1.5 billion. This press release features multimedia. View the full release here: https
Investment will help Orbus accelerate organic and inorganic growth, drive international expansion, and further cement the company's position as the leading AI-driven enterprise architecture platform. Orbus Software ("Orbus"), a global market-leading provider of SaaS enterprise transformation software, today announced a significant growth equity investment from FTV Capital, a sector-focused growth equity investment firm. FTV is investing alongside co-control partner SilverTree Equity, a London-based software specialist investor that has supported Orbus since its investment in December 2020. The investment will fuel Orbus's continued expansion into the United States and other high-growth ma
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced that Enfusion's Chief Financial Officer, Brad Herring, and Chief Operating Officer, Neal Pawar, will participate at the following investor events: Wells Fargo 8th Annual TMT Summit on Tuesday, December 3, 2024 UBS Global Technology and AI Conference on Wednesday, December 4, 2024 Live audio webcasts and archived replays of the events will be available in the Events & Presentations section of the Enfusion Investor Relations website at http://ir.enfusion.com. About Enfusion Enfusion's investment management software-as-a-service platform re
4 - Enfusion, Inc. (0001868912) (Issuer)
4 - Enfusion, Inc. (0001868912) (Issuer)
4 - Enfusion, Inc. (0001868912) (Issuer)